BIAF

SEC filing BIAF Reports $0 Revenue, $0 EPS, Announces CyPath Lung Webinar with 92% Sensitivity, 87% Specificity

6h ago

SEC filing BIAF Announces Mexican Patent Allowance for CyPath Lung, Expanding Global IP Portfolio, 92% Sensitivity, 87% Specificity

6d ago

News bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M

25d ago

SEC filing BIAF Reports $1.4M Revenue, CyPath Lung Sales Up 146% YoY to $361K, Physician Adoption Rises 69%

25d ago

SEC filing BIAF Reports 92% Sensitivity, 87% Specificity for CyPath® Lung in Lung Cancer Detection, Supports Deferral of Invasive Biopsy

49d ago

SEC filing BIAF Hosts Live Virtual Physician Roundtable on CyPath® Lung Integration, 92% Sensitivity, 87% Specificity, April 8, 2026, 7 p.m. ET

68d ago

SEC filing BIAF Launches 2,000-Patient CyPath Lung Longitudinal Study, 92% Sensitivity, 87% Specificity, 20 Sites Including VA Hospitals, NCT07168993

84d ago

SEC filing BIAF Announces Board Exit of Robert Anderson and Roby Joyce Ahead of April 30 Annual Meeting

87d ago

News Biotech Startup M&A Is Reliably Delivering Some Big Exits - Crunchbase News

104d ago

News Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - Nasdaq

108d ago

News Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

108d ago

News Hair Loss Biopharma Firm Veradermics Raises $256 Million in IPO

118d ago

Scanner Unusual volume (3.6x average)

124d ago